Nubacap 25, 75, 150 25mg, 75mg, 150mg CAPSULES
PDF Leaflet Revision Date: 29 May 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of neuropathic pain due to Herpes zoster infections and diabetes.
Dosage (summary)
Starting dose: 75 mg twice daily; may increase to 150 mg twice daily after 3-7 days.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
Pregnancy & Breastfeeding
Not recommended during pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- CNS depressants
- Antidepressants
Contraindications
- Hypersensitivity to pregabalin or inactive ingredients
Common side effects
- Dizziness
- Somnolence
- Weight gain
Counselling Points
- Monitor for signs of suicidal ideation
- Caution advised when driving or operating machinery
- Gradual discontinuation recommended
Serious warnings
- Severe cutaneous adverse reactions
- Risk of respiratory depression
- Potential for misuse and dependence
Important Disclaimer
The Nubacap 25, 75, 150 25mg, 75mg, 150mg CAPSULES professional information leaflet below is the property of Forrester Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
